VIDEO: Expert discusses ‘remarkable’ data from ARCHWAY trial in wet AMD
Click Here to Manage Email Alerts
Nancy M. Holekamp, MD, director of retina services at Pepose Vision Institute in St. Louis, discussed results from the ARCHWAY phase 3 trial of the Port Delivery System with ranibizumab presented at the ASRS annual meeting.
“This treatment was equivalent to monthly ranibizumab injections. In a year’s period of time, you have the initial surgery, a 6-month refill and then a 6-month refill after that,” she said in a video interview with Healio. “That’s really remarkable, and the data is very, very strong.”
However, treatment-emergent adverse events occurred, such as conjunctival retraction and erosion and vitreous hemorrhage, according to Holekamp.
“The ASRS was an excellent forum for discussing this technology that just got FDA approval, and in a fair and balanced way, both the benefits and the risk profile were discussed. I look forward to using it on my patients in clinical practice,” Holekamp said.
Susvimo (ranibizumab injection, Genentech/Roche), previously known as the Port Delivery System with ranibizumab, received FDA approval in October.
Collapse
Jhaveri C, et al. Wet AMD 1 symposium. Presented at: American Society of Retina Specialists meeting; Oct. 8-12, 2021; San Antonio.
Read more about
Click Here to Manage Email Alerts